Industry

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces its participation in upcoming congresses in March. Christine Le Bec, PhD, Head of Analytical Development & QC, will participate in the Innovative Biologics and … [Read more…]

DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James & Associates’ 46th Annual Institutional Investors Conference on Monday, March 3, 2025. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:05 p.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and … [Read more…]

Partnership improves access to great dermatologic care AUSTIN, Texas–(BUSINESS WIRE)–Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, today announced its entry into Utah through a partnership with Dr. Jesse Jensen and his team at West Valley Dermatology, located in West Valley City. Led by Dr. Jensen since 2014, West … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “The Drug Development Process: An Intensive 2 Day Training Online” training has been added to ResearchAndMarkets.com’s offering. This comprehensive course provides an in-depth exploration of the drug development process, from initial discovery through to market approval. Participants will gain a thorough understanding of each phase of drug development, including key scientific, regulatory, and … [Read more…]

Presentations highlight some of SwRI’s critical research projects SAN ANTONIO–(BUSINESS WIRE)–#AnnualMeeting–Southwest Research Institute’s advisory trustees, board of directors and guests gathered at SwRI’s main campus in San Antonio for the Institute’s 77th Annual Meeting. The event featured technical presentations, a business meeting and a campus tour. SwRI staff briefed attendees on research and development that … [Read more…]

After nearly 45 years, the rebrand marks a pivotal point in MultiPlan’s strategic transformation and focus on providing cutting-edge technology and data assets that promote affordability, transparency and quality NEW YORK–(BUSINESS WIRE)–Claritev Corporation (“Claritev” or the “Company”) (NYSE: MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, … [Read more…]

CARB-X awards LimmaTech US$6.5 million to advance clinical development of LBT-SA7 ZURICH–(BUSINESS WIRE)–LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participants have been vaccinated in a Phase 1 controlled study of its multivalent vaccine candidate, LBT-SA7. The candidate is designed to prevent skin … [Read more…]

THESSALON, Ontario–(BUSINESS WIRE)–Community members are waging a valiant struggle to save their hospital and restore its services. An hour east of Sault Ste. Marie, just off the TransCanada Highway on the north shore of Lake Huron, the community hospital in Thessalon is a life saver for its residents… literally. Yet, the local emergency department has … [Read more…]

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, clinical response was maintained in nearly half of patients for Psoriasis Area and Severity Index (PASI) 90 in the POETYK PSO long-term extension trial PRINCETON, N.J.–(BUSINESS … [Read more…]

OSPOMYV™ and XBRYK™ approved by the U.S. Food and Drug Administration (FDA) for all indications referencing Prolia and Xgeva, respectively Samsung Bioepis’ first endocrinology biosimilar to be approved by the FDA – widening its therapeutic areas and portfolios INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has … [Read more…]